Antibody-containing solution pharmaceuticals

Inactive Publication Date: 2005-06-02
CHUGAI PHARMA CO LTD
View PDF4 Cites 109 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] The object of the present invention is to provide an antibody-containing solution formulation that is stable for long-term storage. This formulation is designed to suppress the formation of visible insoluble matter and/or insoluble particles, which are derived from the aggregation

Problems solved by technology

When proteins are stored in a highly concentrated solution form, they are usually associated with a problem of deterioration, including the formation of insoluble aggregates, which is required to be prevented.
However, the anti-HM1.24 antibody is an unstable protein and is more likely to undergo physical and chemical changes (e.g., association, aggregation) as a result of stresses in the purification process.
However, repeating such shaking and freezing-thawing steps causes the formation of antibody aggregates and/or insoluble particles.
Furthermore, long-term storage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody-containing solution pharmaceuticals

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effects of Organic Acid Addition

[0087] Anti-HM1.24 antibody formulations prepared in different buffers (phosphate, acetate, citrate) were supplemented with iron (FeCl3), and observed for the formation of visible insoluble matter by the unaided eye against a black background in accordance with the foreign insoluble matter test. The samples were stored at room temperature (about 25° C.). Table 1 summarizes the composition of tested formulations, and Table 2 shows the results obtained.

TABLE 1Composition of tested formulationsSample No.123456789101112Anti-HM1.242.52.52.52.52.52.52.52.52.52.52.52.5antibody(mg / mL)Polysorbate 800.0250.0250.0250.0250.0250.0250.0250.0250.0250.0250.0250.025(%)Buffer typeAcAcAcAcPhosPhosPhosPhosCitCitCitCitBuffer conc.202020202020202020202020(mM)Sodium100100100100100100100100100100100100chloride(mM)pH6.06.06.06.06.06.06.06.06.06.06.06.0FeCl3 conc.010100100001010010000101001000(μg / L)

Ac: acetate buffer,

Phos: phosphate buffer,

Cit: citrate buffer

[0088]

TABLE ...

example 2

Effects of Surfactant Addition

[0090] Polysorbate 80, Polysorbate 20 and Poloxamer 188 were used in the shaking test, freezing-thawing test and storage stability test of anti-HM1.24 antibody formulations (2.5 to 10 mg / mL) to study surfactant-induced effects on the formulations.

(1) Physical Stress Test

[0091] Surfactant-induced effects on physical stresses (shaking and freezing-thawing) were studied in terms of insoluble particle or visible insoluble matter formation.

(1-1) Test on 2.5 mg / mL Solutions

[0092] The evaluation was conducted as follows. Table 3 shows the composition of tested formulations along with the results obtained. [0093] Test sample: 2 mL per 5 mL vial (Samples 13-22) [0094] Evaluation: insoluble particle test using a light shielding type of an automatic particle analyzer (HIAC) [0095] Evaluation conditions:

(i) Shaking Test [0096] Shaking conditions: 200 strokes / min.×30 min. [0097] Shaker: RECIPRO SHAKER SR-I [0098] (Taiyo Scientific Industrial Co., Ltd.)

(ii...

example 3

Dependency on pH

[0121] To confirm the optimum pH for the anti-HM1.24 antibody in the concentration range of 2.5 to 10 mg / mL, the heat resistance test and the storage stability test were conducted.

(1) Test on 2.5 mg / mL Formulations

[0122] The evaluation was conducted as follows. Tables 7 and 8 show the composition of tested formulations and the results obtained, respectively. [0123] Test sample: 1 mL per 5 mL vial (Samples 43-47) [0124] Evaluation: heat resistance test, storage stability test [0125] Storage conditions: [0126] at 50° C. for 3 moths (50° C.-3M)(GPC)

[0127] at 5° C. for 6 months (5° C.-6M)(IEC)

TABLE 7Composition of tested formulationsSample No.4344454647Anti-HM1.24 antibody2.52.52.52.52.5(mg / mL)Acetate buffer (mM)2020202020Sodium chloride (mM)100100100100100Polysorbate 80 (%)0.0250.0250.0250.0250.025PH5.05.56.06.57.0

[0128]

TABLE 8Evaluation results of heat resistance test (50° C.-3M) andstorage stability test (5° C.-6M)GPC (50° C.-3M)SampleResidueAggregationDecompos...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Molar densityaaaaaaaaaa
Densityaaaaaaaaaa
Login to view more

Abstract

An antibody-containing solution formulation comprising an organic acid and a surfactant as stabilizers; a method for suppressing the formation of visible insoluble matter and/or insoluble particles due to the presence of metal ions in an antibody-containing solution formulation, which comprises adding an organic acid to the solution; a method for suppressing the formation of visible insoluble matter and/or insoluble particles during shaking and freezing-thawing of an antibody-containing solution, which comprises adding a surfactant to the solution; and a method for stabilizing an antibody-containing solution, which comprises adding an organic acid and a surfactant.

Description

TECHNICAL FIELD [0001] The present invention relates to stable solution formulations containing antibodies. BACKGROUND ART [0002] Advances in gene recombination technology have enabled the pharmaceutical use of antibodies such as immunoglobulins, monoclonal antibodies and humanized antibodies. To ensure a stable supply of these antibodies, it is necessary to establish production and storage conditions where the structure and activity of the antibodies can be maintained. [0003] When proteins are stored in a highly concentrated solution form, they are usually associated with a problem of deterioration, including the formation of insoluble aggregates, which is required to be prevented. It is necessary to prevent such deterioration. For example, the applicant has found that an anti-HM1.24 antibody has a therapeutic effect on myeloma cells (JP KOKAI 11-092399), and also has studied formulation of this antibody. However, the anti-HM1.24 antibody is an unstable protein and is more likely t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/00A61K39/395A61K47/04A61K9/08A61K47/10A61K47/12A61K47/14A61K47/26C07K16/30C07K16/40C07K16/44
CPCA61K9/0019C07K16/3061A61K39/39591A61K47/10A61K2039/505A61K47/12C07K16/44A61K47/26C07K16/40C07K16/00A61P37/04A61K47/34A61K39/395A61K9/08
Inventor MIZUSHIMA, HIDEFUMIMIYAUCHI, EIICHI
Owner CHUGAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap